Subsequently, we assessed whether the infection status had an impact on the metabolic efficacy of best-in-class drugs to treat obesity and diabetes, namely the GLP-1 receptor agonist liraglutide and the GLP-1/GIP co-agonist MAR709. This evidence concerns the gene GLP1R and infection.